siRNA-based knockdown of lncRNAs: A new modality to target tumor progression

This study examines the potential of small interfering RNA (siRNA) as a therapeutic agent for cancer targeting long non-coding RNAs (lncRNAs). The article begins with an analysis of the structure and biogenesis of lncRNA. It explains the diverse functions of lncRNAs in cancer, establishing a foundation for assessing approaches to inhibit these molecules. The analysis focuses on the consequences of lncRNA suppression through siRNA on signaling pathways associated with cancer, connecting theoretical understanding to practical applications. An evaluation of ongoing clinical trials and applications contributes to the discourse by revealing the potential for siRNA-mediated interventions to be practiced. Furthermore, an evaluation of the advantages and disadvantages of this therapeutic approach offers a nuanced viewpoint. In conclusion, the paper synthesizes significant discoveries and outlines potential avenues for future research, contributing to the dialogue surrounding personalized cancer therapeutics and precision medicine. Future challenges in using siRNA to target lncRNAs in oncology include optimizing delivery systems for efficient tumor cell uptake, minimizing off-target effects, enhancing RNA stability for a longer therapeutic window, and overcoming barriers in the tumor microenvironment. Addressing these factors is essential for the practical application of siRNA-based cancer therapies.